Loading...
Loading...
Meridian Medical Technologies Patents
Meridian Medical Technologies has filed 11 patents.
The 3 most popular patent topics include:
- drug delivery devices
- medical equipment
- debt bondage
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
6/26/2020 | 12/19/2023 | Individual sailing vessels, Drug delivery devices, Medical equipment, Pfizer products, Debt bondage | Grant |
Application Date | 6/26/2020 |
---|---|
Grant Date | 12/19/2023 |
Title | |
Related Topics | Individual sailing vessels, Drug delivery devices, Medical equipment, Pfizer products, Debt bondage |
Status | Grant |
Latest Meridian Medical Technologies News
Meridian Medical wins $129m US gov contract for nerve agent antidote supply
Jan 16, 2025
Meridian Medical wins $129m US gov contract for nerve agent antidote supplyMeridian’s DuoDote autoinjectors will be manufactured at the Missouri-based facility of Meridian's parent company Kindeva Drug Delivery. ShareMeridian Medical’s DuoDote will be stockpiled as part of the Strategic National Stockpile’s (SNS) CHEMPACK programme. Image credit: Lucky-photographer via Shutterstock. Kindeva Drug Delivery division Meridian Medical Technologies has won a new contract worth up to $129m from the US Government for the supply of its DuoDote chemical nerve agent antidote autoinjectors to the Strategic National Stockpile (SNS). Managed by the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), the SNS contains medicines and devices for lifesaving care, which are intended for use as stopgap buffers when the immediate supply of such materials may not be available or sufficient. Go deeper with GlobalDataThe DuoDote dual-chamber autoinjector contains atropine and pralidoxime chloride and was approved by the US Food and Drug Administration (FDA) in 2006. It is indicated for the treatment of poisoning from organophosphorus nerve agents and organophosphorus insecticides. Perhaps the nerve agent most well-known to the general public, sarin has been in use since World War II and became infamous in more recent times for its 2013 use on civilians in Syria during the Bashar al-Assad regime. The DuoDote autoinjectors will be manufactured at Kindeva Drug Delivery’s facility in St Louis, Missouri. They will then be stockpiled and available for rapid deployment as part of the SNS CHEMPACK programme. SNS CHEMPACK is an ASPR initiative in which containers of nerve agent antidotes are placed in secure locations around the US to enable rapid response to chemical incidents. Kindeva CEO Milton Boyer commented: “As a trusted partner to the SNS, this contract underscores the ongoing importance of maintaining readiness against potential threats. How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sampleWe are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalDataSubmitTick here to opt out of curated industry news, reports, and event updates from Medical Device Network. Submit and downloadVisit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. “Our long-standing partnership with the SNS reflects our commitment to national preparedness and our ability to deliver crucial medical countermeasures when they are needed most. With our extensive experience in this space, we are proud to continue supporting the US Government’s efforts to protect public health and safety.”Kindeva recently partnered with Emervax to co-develop a vaccine delivery solution for viruses including mpox and yellow fever. Kindeva Drug Delivery was formerly known as 3M Drug Delivery Systems and rebranded itself in 2020, following its acquisition by Altaris Capital Partners in a deal valued at $650m. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Jan 16, 2025
Jan 16, 2025
Jan 16, 2025
Meridian Medical Technologies Frequently Asked Questions (FAQ)
When was Meridian Medical Technologies founded?
Meridian Medical Technologies was founded in 1958.
Where is Meridian Medical Technologies's headquarters?
Meridian Medical Technologies's headquarters is located at 6350 Stevens Forest Road, Columbia.
What is Meridian Medical Technologies's latest funding round?
Meridian Medical Technologies's latest funding round is Merger.
How much did Meridian Medical Technologies raise?
Meridian Medical Technologies raised a total of $5.75M.
Who are the investors of Meridian Medical Technologies?
Investors of Meridian Medical Technologies include Kindeva.